🎗️ Endometrial Cancer Mayo Lymphadenectomy Indication
UseIdentify the low-risk endometrioid endometrial cancer group that can omit systematic lymphadenectomy.
Loading calculator…
SourceMariani A, et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?
Runs locally in your browser (no PHI uploaded). For licensed clinicians — not a substitute for clinical judgement.
Stored on this device for revisit reminders
This-shift next steps
After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.
Score + version; reference only — not a substitute for care · no HIS write
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
Methodology · worked example, guidelines & full notes
Clinical takeaway
The low-risk group has roughly 1–5% nodal metastasis and ~ 99% 5-year survival, and can omit systematic dissection without a survival cost.
When to use
Identify the low-risk endometrioid endometrial cancer group that can omit systematic lymphadenectomy.
How it works
Low-risk = endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm (or no myometrial invasion at any size/grade). Any of G3 / > 50% invasion / > 2 cm / non-endometrioid = at-risk.
Key points
- The low-risk group has roughly 1–5% nodal metastasis and ~ 99% 5-year survival, and can omit systematic dissection without a survival cost.
- The at-risk group has roughly 6.4% nodal metastasis and warrants pelvic ± para-aortic dissection or sentinel-node biopsy.
- Non-endometrioid histology (serous/clear-cell/carcinosarcoma) is high-risk regardless and needs full staging.
- Contemporary practice increasingly replaces systematic lymphadenectomy with sentinel-node mapping.
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Histology | Endometrioid adenocarcinoma |
|---|---|
| Grade | G1–2 |
| Myometrial invasion depth | ≤ 50% (inner half) |
| Maximum primary tumour diameter | ≤ 2 cm |
→LymphadenectomyCan be omitted
- Verdict：Low-risk: Endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm — all met (nodal metastasis ~ 1–5%, 5-year survival ~ 99%)
- Management direction：Systematic pelvic/para-aortic lymphadenectomy can be safely omitted (no survival impact); sentinel-node mapping now commonly replaces it
- Notes：Mayo criteria (Mariani 2000/2008): low-risk = endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm (or no myometrial invasion, any size/grade); high-risk (> 50% invasion / G3 / > 2 cm / non-endometrioid) needs node assessment. Contemporary practice often replaces systematic dissection with sentinel-node biopsy
| Histology | Non-endometrioid (serous/clear-cell/carcinosarcoma etc.) |
|---|---|
| Grade | G3 |
| Myometrial invasion depth | > 50% (outer half) |
| Maximum primary tumour diameter | > 2 cm |
→LymphadenectomyDissection/assessment advised
- Verdict：High-risk (at-risk): Non-endometrioid (serous/clear-cell/carcinosarcoma etc.) is high-risk histology and needs systematic staging / node assessment (nodal metastasis ~ 6.4%)
- Management direction：Systematic pelvic ± para-aortic lymphadenectomy is advised, or sentinel-node biopsy to complete staging
- Notes：Mayo criteria (Mariani 2000/2008): low-risk = endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm (or no myometrial invasion, any size/grade); high-risk (> 50% invasion / G3 / > 2 cm / non-endometrioid) needs node assessment. Contemporary practice often replaces systematic dissection with sentinel-node biopsy
Verification & sources · governance
FAQ
Frequently asked questions
- What are the limits and cautions when using Endometrial Cancer Mayo Lymphadenectomy Indication?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- Does Endometrial Cancer Mayo Lymphadenectomy Indication upload patient data? Where is it calculated?
- Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
- How is Endometrial Cancer Mayo Lymphadenectomy Indication calculated in practice? Can you show a worked example?
- Inputs: Histology Endometrioid adenocarcinoma, Grade G1–2, Myometrial invasion depth ≤ 50% (inner half), Maximum primary tumour diameter ≤ 2 cm → Result: Lymphadenectomy Can be omitted（Verdict: Low-risk: Endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm — all met (nodal metastasis ~ 1–5%, 5-year survival ~ 99%), Management direction: Systematic pelvic/para-aortic lymphadenectomy can be safely omitted (no survival impact); sentinel-node mapping now commonly replaces it, Notes: Mayo criteria (Mariani 2000/2008): low-risk = endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm (or no myometrial invasion, any size/grade); high-risk (> 50% invasion / G3 / > 2 cm / non-endometrioid) needs node assessment. Contemporary practice often replaces systematic dissection with sentinel-node biopsy） Inputs: Histology Non-endometrioid (serous/clear-cell/carcinosarcoma etc.), Grade G3, Myometrial invasion depth > 50% (outer half), Maximum primary tumour diameter > 2 cm → Result: Lymphadenectomy Dissection/assessment advised（Verdict: High-risk (at-risk): Non-endometrioid (serous/clear-cell/carcinosarcoma etc.) is high-risk histology and needs systematic staging / node assessment (nodal metastasis ~ 6.4%), Management direction: Systematic pelvic ± para-aortic lymphadenectomy is advised, or sentinel-node biopsy to complete staging, Notes: Mayo criteria (Mariani 2000/2008): low-risk = endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm (or no myometrial invasion, any size/grade); high-risk (> 50% invasion / G3 / > 2 cm / non-endometrioid) needs node assessment. Contemporary practice often replaces systematic dissection with sentinel-node biopsy）